SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: sjemmeri6/9/2011 1:55:29 PM
2 Recommendations   of 10345
 
UBS upgraded Elan Corp (ELN, $10.22, +$0.56, +5.80%) (ELN.DB) to buy from neutral and added it to its top 20 key calls list. The firm said a proprietary survey of multiple sclerosis specialists suggests the market position of Elan's MS drug Tysabri against Novartis' (NOVN.VX) Gilenya is secure. As a result, UBS raised its 2015 Tysabri sales estimate to $2.6 billion from $2.1 billion, well ahead of consensus.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News